



## Clinical trial results:

### A Phase 2, multicenter, open-label study of BGJ398 in patients with recurrent resectable or unresectable glioblastoma

#### Summary

EudraCT number	2013-002200-13
Trial protocol	IT NL ES BE DE
Global end of trial date	03 October 2018

#### Results information

Result version number	v1 (current)
This version publication date	17 October 2019
First version publication date	17 October 2019

#### Trial information

##### Trial identification

Sponsor protocol code	BGJ398X2201
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01975701
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Novartis Pharmaceuticals
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	clinical disclosure office, Novartis Pharma, 41 613241111, novartis.email@novartis.com
Scientific contact	Study Director, Novartis Pharmaceuticals, 41 613241111, novartis.email@novartis.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 October 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	03 October 2018
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

the main objective for this trial was to assess the anti-tumor activity of BGJ398 for patients with GBM and/or other glioma subtypes with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1,2 or 3, based on progression-free survival rate at 6 month (PFS6)

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 December 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	Netherlands: 2
Country: Number of subjects enrolled	Spain: 4
Country: Number of subjects enrolled	Switzerland: 3
Country: Number of subjects enrolled	United States: 16
Worldwide total number of subjects	26
EEA total number of subjects	7

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	21
From 65 to 84 years	5
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

All 26 patients included were enrolled in the non Surgical arm.

Note : Australia participated in this trial, however no patients received treatment.

### Pre-assignment

Screening details: -

### Pre-assignment period milestones

Number of subjects started	26
Number of subjects completed	26

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	BGJ398 non surgical
-----------	---------------------

Arm description:

125 mg BGJ398 non surgical

Arm type	experimental
Investigational medicinal product name	BGJ398
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

BGJ398 25 mg

BGJ398 100 mg

hard gelatin capsules for oral use

<b>Number of subjects in period 1</b>	BGJ398 non surgical
Started	26
Completed	1
Not completed	25
Adverse event, serious fatal	23
Physician decision	1
Lost to follow-up	1



## Baseline characteristics

### Reporting groups

Reporting group title	BGJ398 non surgical
-----------------------	---------------------

Reporting group description:

125 mg BGJ398 non surgical

Reporting group values	BGJ398 non surgical	Total	
Number of subjects	26	26	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	21	21	
From 65-84 years	5	5	
85 years and over	0	0	
Age Continuous			
Units: years			
arithmetic mean	53.7		
standard deviation	± 13.59	-	
Sex: Female, Male			
Units: Subjects			
Female	10	10	
Male	16	16	
Race/Ethnicity, Customized			
Units: Subjects			
caucasian	26	26	

## End points

### End points reporting groups

Reporting group title	BGJ398 non surgical
Reporting group description: 125 mg BGJ398 non surgical	

### Primary: progression free survival

End point title	progression free survival <sup>[1]</sup>
End point description: To assess the anti-tumor activity of BGJ398 for patients with GBM and/or other glioma subtypes that harbor FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 or 3 based on PFS6 (PFS rate at 6 months as defined by RANO criteria as assessed by the investigator)	
End point type	Primary
End point timeframe: 6 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: no Analysis was performed

<b>End point values</b>	BGJ398 non surgical			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: months				
median (confidence interval 95%)	1.7 (1.05 to 2.80)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Overall response rate

End point title	Overall response rate
End point description: To further assess the anti-tumor activity of BGJ398 for patients with GBM with an amplification, translocation, or activating mutation in FGFR1,2,3 or 4, based on Objective Response Rate (ORR - patients with measurable disease - as defined by RANO criteria as assessed by the investigator)	
End point type	Secondary
End point timeframe: 8 months after last patient last visit	

<b>End point values</b>	BGJ398 non surgical			
Subject group type	Reporting group			
Number of subjects analysed	26			
Units: participants				
partial response	2			
stable disease	7			
progressive disease	13			
unknown	3			
missing	1			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall survival

End point title	Overall survival
End point description:	
To further assess the anti-tumor activity of BGJ398 for patients with GBM and/or other glioma subtypes that harbor FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 and 3 based on Overall Survival	
End point type	Secondary
End point timeframe:	
8 months after LPLV	

<b>End point values</b>	BGJ398 non surgical			
Subject group type	Reporting group			
Number of subjects analysed	26			
Units: months				
median (confidence interval 95%)	6.74 (4.17 to 11.73)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: safety and tolerability

End point title	safety and tolerability
End point description:	
Safety: type, frequency, and severity of AEs and SAEs; Tolerability: dose interruptions, reductions and dose intensity, and evaluations of laboratory values	
End point type	Secondary
End point timeframe:	
8 months after LPLV	



<b>End point values</b>	BGJ398 non surgical			
Subject group type	Reporting group			
Number of subjects analysed	26			
Units: participants				
participants with dose interruptions	13			
participants with dose reductions	4			

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

5 years

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

### Reporting groups

Reporting group title	All@Patients
-----------------------	--------------

Reporting group description:

All@Patients

Reporting group title	Non Surg BGJ398@125 mg
-----------------------	------------------------

Reporting group description:

Non Surg BGJ398@125 mg

Serious adverse events	All@Patients	Non Surg BGJ398@125 mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 26 (34.62%)	9 / 26 (34.62%)	
number of deaths (all causes)	3	3	
number of deaths resulting from adverse events	0	0	
Investigations			
Decreased appetite			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Cataract operation			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Ataxia			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			

subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurological decompensation			
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Neurological symptom			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
General physical health deterioration			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Cataract			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperphosphataemia			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	All@Patients	Non Surg BGJ398@125 mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	26 / 26 (100.00%)	26 / 26 (100.00%)	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)	
occurrences (all)	4	4	
Fatigue			
subjects affected / exposed	9 / 26 (34.62%)	9 / 26 (34.62%)	
occurrences (all)	9	9	
Gait disturbance			
subjects affected / exposed	3 / 26 (11.54%)	3 / 26 (11.54%)	
occurrences (all)	3	3	
Mucosal inflammation			
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)	
occurrences (all)	5	5	
Oedema peripheral			

subjects affected / exposed occurrences (all)	3 / 26 (11.54%) 3	3 / 26 (11.54%) 3	
Cyst subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Pain subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Reproductive system and breast disorders			
Bartholin's cyst subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 2	1 / 26 (3.85%) 2	
Vaginal haemorrhage subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 2	2 / 26 (7.69%) 2	
Epistaxis subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 4	2 / 26 (7.69%) 4	
Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 3	2 / 26 (7.69%) 3	
Hiccups subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Nasal inflammation subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Sinus congestion subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Psychiatric disorders			

Anxiety			
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)	
occurrences (all)	2	2	
Confusional state			
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)	
occurrences (all)	2	2	
Depression			
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)	
occurrences (all)	2	2	
Insomnia			
subjects affected / exposed	4 / 26 (15.38%)	4 / 26 (15.38%)	
occurrences (all)	4	4	
Agitation			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Investigations			
Thrombocytopenia			
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)	
occurrences (all)	2	2	
Alanine aminotransferase increased			
subjects affected / exposed	3 / 26 (11.54%)	3 / 26 (11.54%)	
occurrences (all)	3	3	
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 26 (11.54%)	3 / 26 (11.54%)	
occurrences (all)	4	4	
Blood alkaline phosphatase increased			
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)	
occurrences (all)	2	2	
Leukopenia			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	3	3	
Neutropenia			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Amylase increased			

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 26 (3.85%)</p> <p>1</p>	<p>1 / 26 (3.85%)</p> <p>1</p>	
<p>Blood bilirubin increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 26 (3.85%)</p> <p>2</p>	<p>1 / 26 (3.85%)</p> <p>2</p>	
<p>Weight decreased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 26 (3.85%)</p> <p>1</p>	<p>1 / 26 (3.85%)</p> <p>1</p>	
<p>White blood cell count decreased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 26 (3.85%)</p> <p>1</p>	<p>1 / 26 (3.85%)</p> <p>1</p>	
<p>Injury, poisoning and procedural complications</p> <p>Fall</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 26 (7.69%)</p> <p>3</p>	<p>2 / 26 (7.69%)</p> <p>3</p>	
<p>Traumatic haematoma</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 26 (3.85%)</p> <p>1</p>	<p>1 / 26 (3.85%)</p> <p>1</p>	
<p>Cardiac disorders</p> <p>Palpitations</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 26 (3.85%)</p> <p>1</p>	<p>1 / 26 (3.85%)</p> <p>1</p>	
<p>Sinus bradycardia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 26 (3.85%)</p> <p>1</p>	<p>1 / 26 (3.85%)</p> <p>1</p>	
<p>Nervous system disorders</p> <p>Aphasia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 26 (11.54%)</p> <p>3</p>	<p>3 / 26 (11.54%)</p> <p>3</p>	
<p>Dizziness</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 26 (7.69%)</p> <p>2</p>	<p>2 / 26 (7.69%)</p> <p>2</p>	
<p>Headache</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 26 (23.08%)</p> <p>6</p>	<p>6 / 26 (23.08%)</p> <p>6</p>	
<p>Hemiparesis</p>			

subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)
occurrences (all)	2	2
Memory impairment		
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)
occurrences (all)	2	2
Seizure		
subjects affected / exposed	4 / 26 (15.38%)	4 / 26 (15.38%)
occurrences (all)	4	4
Somnolence		
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)
occurrences (all)	2	2
Tremor		
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)
occurrences (all)	2	2
Anosmia		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Ataxia		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Cognitive disorder		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Dysaesthesia		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Dysgeusia		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Facial paresis		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Hemianopia		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Horner's syndrome		



subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Paraesthesia			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 26 (11.54%)	3 / 26 (11.54%)	
occurrences (all)	3	3	
Eye disorders			
Dry eye			
subjects affected / exposed	3 / 26 (11.54%)	3 / 26 (11.54%)	
occurrences (all)	3	3	
Eyelid ptosis			
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)	
occurrences (all)	2	2	
Cataract			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	2	2	
Conjunctival hyperaemia			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Corneal infiltrates			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Eye irritation			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Keratopathy			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	2	2	
Ocular hyperaemia			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Gastrointestinal disorders			

Constipation		
subjects affected / exposed	7 / 26 (26.92%)	7 / 26 (26.92%)
occurrences (all)	8	8
Diarrhoea		
subjects affected / exposed	8 / 26 (30.77%)	8 / 26 (30.77%)
occurrences (all)	11	11
Dyspepsia		
subjects affected / exposed	7 / 26 (26.92%)	7 / 26 (26.92%)
occurrences (all)	7	7
Stomatitis		
subjects affected / exposed	5 / 26 (19.23%)	5 / 26 (19.23%)
occurrences (all)	10	10
Aphthous ulcer		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Dry mouth		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Gastritis		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Gastrointestinal haemorrhage		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Glossodynia		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Haematochezia		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Haemorrhoids		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Lip dry		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1

Lip pain			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Nausea			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Odynophagia			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Oral disorder			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Oral pain			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Vomiting			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	4 / 26 (15.38%)	4 / 26 (15.38%)	
occurrences (all)	4	4	
Dermatitis acneiform			
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)	
occurrences (all)	2	2	
Dry skin			
subjects affected / exposed	4 / 26 (15.38%)	4 / 26 (15.38%)	
occurrences (all)	5	5	
Nail disorder			
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)	
occurrences (all)	2	2	
Onycholysis			
subjects affected / exposed	3 / 26 (11.54%)	3 / 26 (11.54%)	
occurrences (all)	6	6	
Palmar-plantar erythrodysaesthesia syndrome			

subjects affected / exposed	3 / 26 (11.54%)	3 / 26 (11.54%)
occurrences (all)	4	4
Skin ulcer		
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)
occurrences (all)	2	2
Blister		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Dermatitis bullous		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Erythema		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Hyperkeratosis		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	2	2
Hypertrichosis		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Nail dystrophy		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Onychalgia		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	2	2
Rash maculo-papular		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Skin disorder		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Skin exfoliation		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Skin irritation		

subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Xeroderma subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Renal and urinary disorders Urinary incontinence subjects affected / exposed occurrences (all)	4 / 26 (15.38%) 4	4 / 26 (15.38%) 4	
Chromaturia subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 4	2 / 26 (7.69%) 4	
Muscular weakness subjects affected / exposed occurrences (all)	4 / 26 (15.38%) 6	4 / 26 (15.38%) 6	
Musculoskeletal pain subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 2	2 / 26 (7.69%) 2	
Myalgia subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 2	2 / 26 (7.69%) 2	
Pain in extremity subjects affected / exposed occurrences (all)	3 / 26 (11.54%) 4	3 / 26 (11.54%) 4	
Infections and infestations Conjunctivitis subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 2	2 / 26 (7.69%) 2	

Oral candidiasis		
subjects affected / exposed	2 / 26 (7.69%)	2 / 26 (7.69%)
occurrences (all)	2	2
Folliculitis		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Fungal skin infection		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	2	2
Herpes simplex		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Hordeolum		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Lip infection		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Nasopharyngitis		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Oral herpes		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Paronychia		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Pharyngitis		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Rash pustular		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1
Rhinitis		
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)
occurrences (all)	1	1

Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Wound infection subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	4 / 26 (15.38%) 4	4 / 26 (15.38%) 4	
Hyperglycaemia subjects affected / exposed occurrences (all)	3 / 26 (11.54%) 5	3 / 26 (11.54%) 5	
Hyperlipasaemia subjects affected / exposed occurrences (all)	4 / 26 (15.38%) 5	4 / 26 (15.38%) 5	
Hyperphosphataemia subjects affected / exposed occurrences (all)	20 / 26 (76.92%) 43	20 / 26 (76.92%) 43	
Hyponatraemia subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 4	2 / 26 (7.69%) 4	
Hypophosphataemia subjects affected / exposed occurrences (all)	4 / 26 (15.38%) 11	4 / 26 (15.38%) 11	
Hypercalcaemia subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Hypercreatininaemia subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 2	1 / 26 (3.85%) 2	
Hyperkalaemia subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	
Hypernatraemia			

subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Hyperuricaemia			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Hypoalbuminaemia			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	3	3	
Hypokalaemia			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 August 2014	exclusion criteria were updated to exclude patients with current evidence of corneal/keratopathy or retinal disorder, ophthalmologic eye exam assessments were added, patients with clinically significant hypokalemia were excluded
01 April 2015	Inclusion/Exclusion criteria were modified to exclude patients with FGFR1, 2, 3, and 4 amplifications and to include GBM and/or other glioma subtype patients with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutations in FGFR1, 2 or 3 gene.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

decision was made not to pursue further development for this disease indication. BGJ398 was out licensed and the indication was no longer pursued. Remaining patient continued treatment in post-trial settings.

Notes: